Marina Sokolsky‐Papkov

Myeloid compartment reprogramming through nanoparticle delivered resiquimod blocks paracrine growth support and activates phagocytosis to slow tumor progression in endogenous mouse medulloblastoma and diffuse midline glioma models

ResiPOx, a nanoparticle-delivered TLR7/8 agonist, reprograms tumor-associated myeloid cells to inhibit tumor growth in mouse models of medulloblastoma and diffuse midline glioma.

In vitro efficacy and in vivo toxicity and retention of targeted nanoformulated carboplatin in a sustained release carrier for treatment of osteosarcoma

Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity

This paper develops a nanoparticle formulation of vismodegib that improves its efficacy for medulloblastoma treatment by enhancing CNS pharmacokinetics and reducing systemic toxicity.